Boston Scientific CEO Mahoney Buys More Than 200k Shares for $10 Million. What Does This Mean for Investors in 2026?

Written by Brendan Coffey for The Motley Fool

Michael F. Mahoney deployed ~$10.0 million on August 3, 2026, to acquire ~200,000 shares at a weighted average price of $48.34.

The acquisition increased the CEO's total equity holdings by 13%, primarily expanding his direct position in the company.

Part of the transaction was executed as a discretionary rebalancing within the executive's 401(k) retirement plan, where he holds 22,119 shares indirectly.

The purchase occurred as shares were priced at levels reflecting a -54% one-year total return as of the August 3, 2026 transaction date.

Michael F. Mahoney, Chairman, President & CEO of Boston Scientific Corporation (NYSE:BSX), purchased 186,240 shares of common stock at $48.34 per share on August 3, 2026. SEC Form 4 filing.

Transaction value based on SEC Form 4 weighted average purchase price ($48.34); post-transaction value based on August 03, 2026 market close ($48.43).

Boston Scientific Corporation is a global leader in medical technology with a market capitalization of $73 billion and trailing twelve-month (TTM) revenue of $21 billion, employing 59,000 professionals across its operations. The company maintains a diversified business model spanning three strategic segments that collectively address a broad spectrum of clinical needs in interventional medicine. With a TTM net income of $3.7 billion, Boston Scientific demonstrates strong operational profitability and positions itself as a key innovator in the medical device sector, competing on the basis of technological advancement, clinical efficacy, andglobal marketreach.

There are many reasons an insider may sell shares in a company. One reason could be the need to raise cash to pay for a large personal expense. Another reason could be for reasonable portfolio diversification unrelated to their outlook for the company. A third reason could be what investors fear most: a bearish outlook on the company’s future.

However, there is only one reason an insider buys stock: they believe the share price is going up.

By this Wall Street rule of thumb, Mahoney’s purchase of more than $10 million of Boston Scientific shares is bullish. Adding to the bullishness is that studies show an insider purchase presages a higher share price 30 days later, more often than not.

The size of Mahoney’s purchase is significant, too. Hard data is tough to find , but very few insider purchase transactions in any one year are for more than $10 million, across the stock market, especially when you exclude investment funds and just focus on individuals.

Boston Scientific has been having a tough 2026, with management having twice cut revenue guidance due to a competitive marketplace. But the company’s future is looking brighter thanks to acquisitions that now mean the company has a robust pipeline of new products due to hit the market in 2027 through 2029. Mahoney is also leading a restructuring that promises to cut $500 million of fat from operations going into 2027.

An insider purchase of stock is no guarantee shares will go higher, but a sizable statement by a CEO like Mahoney is a signal that investors should take a close look at Boston Scientific shares.

Before you buy stock in Boston Scientific, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Boston Scientific wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $399,832!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,374,595!*

Now, it’s worth noting Stock Advisor’s total average return is 968% — a market-crushing outperformance compared to 215% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

*Stock Advisor returns as of August 10, 2026.

Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.